Suppr超能文献

单胺氧化酶抑制剂及其他一些药物对哌替啶N-去甲基化的抑制作用分析,特别涉及人体中的药物相互作用。

Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man.

作者信息

Clark B, Thompson J W, Widdrington G

出版信息

Br J Pharmacol. 1972 Jan;44(1):89-99. doi: 10.1111/j.1476-5381.1972.tb07241.x.

Abstract
  1. N-Demethylation of pethidine was studied in microsomal suspensions from unstarved male rat liver and the N-demethylase identified as belonging to the class of hepatic microsomal mixed function oxidases.2. A study of the structure/action relationships of compounds inhibiting pethidine N-demethylase revealed that hydrazine derivatives including phenylhydrazine, methylphenylhydrazine and mebanazine were all potent competitive inhibitors.3. Pethidine N-demethylase was only slightly inhibited by histamine and amphetamine but not by adrenaline and ephedrine nor by several miscellaneous compounds including piperidine, N-ethylpiperidine, N-methylpiperidine, N-methylammonium, hydrallazine or pethidinic acid.4. Several psychotropic drugs were all found to be potent competitive inhibitors of pethidine N-demethylase. These included monoaminoxidase inhibitors (the most active being nialamide and phenoxypropazine [K(i)=0.01 mM]; the least active iproniazid [K(i)=1.05 mM]); the tranquillizers promazine, propiomazine and chlorpromazine and tricyclic antidepressants (opipramol [K(i)=0.01 mM], imipramine [K(i)=0.03 mM], desipramine [K(i)=0.03 mM] and amitryptyline [K(i)=0.03 mM]). Hydrocortisone [K(i)=0.3 mM], prednisolone [2.8 mM] and nalorphine [0.07 mM] were also inhibitors, whilst SKF 525A was the most active of all [K(i)=0.002 mM].5. These results are discussed in relation to the clinically observed drug interactions which may occur between monoamineoxidase inhibitors and pethidine. It is concluded that since many different groups of drugs, including monoamineoxidase inhibitors, tranquillizers, tricyclic antidepressants, steroids, nalorphine, SKF 525A and barbiturates compete for cytochrome P(450) reductase, it is possible that this mechanism may account, at least in part, for the observed interactions of these various drugs in man.
摘要
  1. 研究了未饥饿雄性大鼠肝脏微粒体悬浮液中哌替啶的N - 去甲基化反应,并确定N - 去甲基酶属于肝微粒体混合功能氧化酶类。

  2. 对抑制哌替啶N - 去甲基酶的化合物的结构/活性关系研究表明,包括苯肼、甲基苯肼和吗氯贝胺在内的肼衍生物都是有效的竞争性抑制剂。

  3. 组胺和苯丙胺对哌替啶N - 去甲基酶仅有轻微抑制作用,肾上腺素、麻黄碱以及包括哌啶、N - 乙基哌啶、N - 甲基哌啶、N - 甲基铵、肼屈嗪或哌替啶酸在内的几种其他化合物对其无抑制作用。

  4. 发现几种精神药物都是哌替啶N - 去甲基酶的有效竞争性抑制剂。这些药物包括单胺氧化酶抑制剂(活性最强的是尼亚酰胺和苯氧丙嗪[K(i)=0.01 mM];活性最弱的是异烟肼[K(i)=l.05 mM]);镇静剂丙嗪、丙酰丙嗪和氯丙嗪以及三环类抗抑郁药(奥匹哌醇[K(i)=0.01 mM]、丙咪嗪[K(i)=0.03 mM]、地昔帕明[K(i)=0.03 mM]和阿米替林[K(i)=0.03 mM])。氢化可的松[K(i)=0.3 mM]、泼尼松龙[2.8 mM]和纳洛啡[0.07 mM]也是抑制剂,而SKF 525A是所有抑制剂中活性最强的[K(i)=0.002 mM]。

  5. 结合单胺氧化酶抑制剂与哌替啶之间临床上观察到的药物相互作用对这些结果进行了讨论。得出的结论是,由于许多不同类别的药物,包括单胺氧化酶抑制剂、镇静剂、三环类抗抑郁药、类固醇、纳洛啡、SKF 525A和巴比妥类药物都竞争细胞色素P(450)还原酶,所以这种机制可能至少部分地解释了在人体中观察到的这些不同药物之间的相互作用。

相似文献

2
Effect of monoamine oxidase inhibitors on the N-demethylation and hydrolysis of meperidine.
Biochem Pharmacol. 1970 Jul;19(7):2243-50. doi: 10.1016/0006-2952(70)90123-1.
8
Effect of monoamine oxidase inhibitors on the disposition of intracisternally administered metaraminol-3H.
Biochem Pharmacol. 1970 Feb;19(2):525-32. doi: 10.1016/0006-2952(70)90209-1.
10
Inhibition of the metabolism of H3-melatonin by phenothiazines.
J Pharmacol Exp Ther. 1968 Jun;161(2):367-72.

引用本文的文献

3
Clinical pharmacokinetics of pethidine: 1982.哌替啶的临床药代动力学:1982年。
Clin Pharmacokinet. 1982 Sep-Oct;7(5):421-33. doi: 10.2165/00003088-198207050-00003.
7
Pharmacokinetic drug interactions in anaesthetic practice.麻醉实践中的药代动力学药物相互作用。
Clin Pharmacokinet. 1991 Oct;21(4):285-307. doi: 10.2165/00003088-199121040-00005.
9
Metabolism of phenazone in man after hydrocortisone administration.
Eur J Clin Pharmacol. 1978 Mar 17;13(1):69-72. doi: 10.1007/BF00606685.

本文引用的文献

9
Studies on an N-demethylating system in rat liver microsomes.
J Pharmacol Exp Ther. 1961 Mar;131:275-81.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验